Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Leases (2019 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Current Leases for 7 consecutive years, with $18.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 9.6% year-over-year to $18.4 million, compared with a TTM value of $18.4 million through Dec 2025, up 9.6%, and an annual FY2025 reading of $18.4 million, up 9.6% over the prior year.
  • Current Leases was $18.4 million for Q4 2025 at Agios Pharmaceuticals, up from $18.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $18.4 million in Q4 2025 and bottomed at $250000.0 in Q1 2022.
  • Average Current Leases over 5 years is $13.0 million, with a median of $14.5 million recorded in 2023.
  • The sharpest move saw Current Leases tumbled 96.87% in 2022, then skyrocketed 5496.8% in 2023.
  • Year by year, Current Leases stood at $10.8 million in 2021, then rose by 26.18% to $13.7 million in 2022, then rose by 9.84% to $15.0 million in 2023, then rose by 11.81% to $16.8 million in 2024, then increased by 9.6% to $18.4 million in 2025.
  • Business Quant data shows Current Leases for AGIO at $18.4 million in Q4 2025, $18.0 million in Q3 2025, and $17.6 million in Q2 2025.